Stoke Therapeutics

Stoke Therapeutics

Biotechnology, 45 Wiggins Ave, Bedford, Massachusetts, 01730, United States, 51-200 Employees

stoketherapeutics.com

  • twitter
  • LinkedIn

phone no Phone Number: 78********

Who is STOKE THERAPEUTICS

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases. The company is pursuing an entirely new approach to treating...

Read More

map
  • 45 Wiggins Ave, Bedford, Massachusetts, 01730, United States Headquarters: 45 Wiggins Ave, Bedford, Massachusetts, 01730, United States
  • 2017 Date Founded: 2017
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 561110 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from STOKE THERAPEUTICS

Stoke Therapeutics Org Chart and Mapping

Employees

Chia-Ching Lin

Associate Principal Scientist

Sherry Leonard

Senior Director Regulatory Affairs

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Stoke Therapeutics

Answer: Stoke Therapeutics's headquarters are located at 45 Wiggins Ave, Bedford, Massachusetts, 01730, United States

Answer: Stoke Therapeutics's phone number is 78********

Answer: Stoke Therapeutics's official website is https://stoketherapeutics.com

Answer: Stoke Therapeutics's revenue is $1 Million to $5 Million

Answer: Stoke Therapeutics's SIC: 2834

Answer: Stoke Therapeutics's NAICS: 561110

Answer: Stoke Therapeutics has 51-200 employees

Answer: Stoke Therapeutics is in Biotechnology

Answer: Stoke Therapeutics contact info: Phone number: 78******** Website: https://stoketherapeutics.com

Answer: Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases. The company is pursuing an entirely new approach to treating severe diseases. We are initially focused on diseases of the central nervous system and the eye, with an emphasis on haploinsufficiencies, which are diseases caused by a loss of about half of the normal protein function. Rather than replace, repair or edit faulty genes, we aim to increase or stoke protein output from healthy genes to restore functional protein levels using our proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. In all, Stoke has identified ~6500 genes with a TANGO signature, representing broad potential for our approach to help people with severe diseases. The early results have been promising. Stokes first medicine in development, STK-001 has demonstrated positive Phase 1/2 results for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy that is associated with a number of debilitating non-seizure comorbidities. Behind that, is STK-002, a potential treatment for autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Clinical studies of STK-002 are anticipated to start in 2024. The company is pursuing potential treatments for three additional neurodevelopmental disorders, including Syngap1 and Rett syndrome, in collaboration with Acadia Pharmaceuticals. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access